Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mutual’s Mr. Mucus?

This article was originally published in The Tan Sheet

Executive Summary

United Research Labs/ Mutual Pharmaceutical have filed an ANDA for a generic version of Adams Respiratory Therapeutics single-ingredient, extended-release guaifenesin cough product Mucinex, the firms announce Aug. 18. Adams will urge FDA to apply the same "rigorous scientific criteria" Mucinex was subject to for its original OTC approval, the firm says the same day, noting Mutual's ANDA is for "an older, well-known matrix technology." Adams previously worked with the older technology, "but the FDA did not accept the resulting drug release profile and required a higher scientific standard for product approval," which led the firm to develop the bi-layer technology used in Mucinex, CEO Michael Valentino said during an Aug. 18 call. Mutual asserts its product will meet bioequivalence standards, Adams will "vigorously defend its exclusive market position" as well as its patent portfolio for the brand, Valentino says. Mucinex' approval drove a number of prescription guaifenesin products off the market (1"The Tan Sheet" March 3, 2003, p. 4)...

You may also be interested in...



Adams To File Citizen Petition In Move To Block Generic Mucinex

Adams Respiratory Therapeutics is planning to file a citizen petition in an attempt to fend off generic competition against its 600 mg and 1200 mg Mucinex product (extended-release guaifenesin)

Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says

Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs

Health And Wellness Trademark Review 2 March, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel